Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last kr51.00 SEK
Change Today -0.25 / -0.49%
Volume 58.7K
NVP On Other Exchanges
Symbol
Exchange
Stockholm
OTC US
Frankfurt
As of 11:32 AM 04/1/15 All times are local (Market data is delayed by at least 15 minutes).

neurovive pharmaceutical (NVP) Snapshot

Open
kr51.25
Previous Close
kr51.25
Day High
kr51.75
Day Low
kr49.90
52 Week High
08/5/14 - kr82.00
52 Week Low
04/29/14 - kr21.90
Market Cap
1.5B
Average Volume 10 Days
53.7K
EPS TTM
kr-1.79
Shares Outstanding
29.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for NEUROVIVE PHARMACEUTICAL (NVP)

Related News

No related news articles were found.

neurovive pharmaceutical (NVP) Related Businessweek News

No Related Businessweek News Found

neurovive pharmaceutical (NVP) Details

NeuroVive Pharmaceutical AB (publ) researches and develops mitochondrial-protecting pharmaceuticals in Sweden and Hong Kong. Its product portfolio includes CicloMulsion, a drug candidate, which is in Phase III clinical study for reperfusion injury in vasodilation and vasoreinforcement following myocardial infarction; and NeuroSTAT, a drug candidate that is in Phase IIa clinical study for the treatment of traumatic brain injuries. The company is also developing NVP019, an intravenous formulation that is in pre-clinical phase treatment of acute cardiovascular disease and acute brain injury; NVP014 for the treatment of acute ischemic stroke; and NVP015, an orphan drug, which is in pre-clinical development phase for the treatment of primary mitochondrial diseases. It has a collaboration agreement with the Isomerase Therapeutics for the development and commercialization of the cyclophilin-inhibiting molecules. The company was founded in 2000 and is headquartered in Lund, Sweden.

Founded in 2000

neurovive pharmaceutical (NVP) Top Compensated Officers

Chief Executive Officer
Total Annual Compensation: kr2.0M
Compensation as of Fiscal Year 2014.

neurovive pharmaceutical (NVP) Key Developments

NeuroVive Pharmaceutical AB Elects Fredrik Olsson as Board Member

NeuroVive Pharmaceutical AB held its Annual General Meeting on 30 March 2015. At the meeting, Fredrik Olsson was new-elected Board member.

Neurovive Pharmaceutical AB Reports Group and Parent Earnings Results for the Fourth Quarter and Twelve Months Ended December 31, 2014

NeuroVive Pharmaceutical AB reported group and parent earnings results for the fourth quarter and twelve months ended December 31, 2014. For the quarter, on group basis, the company' loss before tax was SEK 17,346,000 against profit before tax of SEK 9,169,000. Diluted loss per share were SEK 0.59 against SEK 0.45 per share a year ago. Operating loss was SEK 17.45 million compared to SEK 9.29 million a year ago. The operating loss for the full year was positively impacted from the revenues from OnCore BioPharma. The operating loss is however higher than corresponding periods of the previous year due to increased operating expenses. Loss was SEK 17.35 million compared to SEK 9.17 million a year ago. Loss attributable to parent company shareholders was SEK 16.31 million compared to SEK 8.54 million a year ago. Cash flow used in operating activities was SEK 1.31 million compared to SEK 4.63 million a year ago. Acquisition of tangible assets was SEK 149,000 compared to SEK 41,000 a year ago. Acquisition of intangible assets was SEK 7.87 million compared to SEK 3.87 million a year ago. For twelve months, on group basis, the company's net revenues were SEK 7,152,000 against SEK 5,335,000. Loss before tax was SEK 44,673 against SEK 22,126,000 a year ago. Diluted loss per share were SEK 1.53 against SEK 1.17 per share a year ago. Operating loss was SEK 45.25 million compared to SEK 22.35 million a year ago. Loss was SEK 44.67 million compared to SEK 22.13 million a year ago. Loss attributable to parent company shareholders was SEK 42.55 million compared to SEK 22.33 million a year ago. Cash flow used in operating activities was SEK 43.63 million compared to SEK 19.09 million a year ago. Acquisition of tangible assets was SEK 178,000 compared to SEK 69,000 a year ago. Acquisition of intangible assets was SEK 23.25 million compared to SEK 11.62 million a year ago. For the quarter, on parent basis, the company's operating income was SEK 14.02 million compared to loss of SEK 7.07 million a year ago. Profit before tax was SEK 14.06 million compared to loss of SEK 7.07 million a year ago. Profit was SEK 14.06 million compared to loss of SEK 7.07 million a year ago. For the year, on parent basis, the company's net sales were SEK 7.55 million compared to SEK 0.819 million a year ago. Operating loss was SEK 10.32 million compared to SEK 23.23 million a year ago. Loss before tax was SEK 9.64 million compared to SEK 22.81 million a year ago. Loss was SEK 9.64 million compared to SEK 22.81 million a year ago.

NeuroVive Plans To List NeuroVive Pharmaceutical Asia On Stock Exchange

NeuroVive Pharmaceutical AB (OM:NVP) has raised $3.3 million from Taiwanese investors to finance early aspects of its Asian expansion. The fundraising moves NeuroVive a step closer to realizing its plan to list NeuroVive Pharmaceutical Asia, Inc. on the Taiwan stock exchange. "The market for the biotech and pharmaceutical industry in Taiwan is currently favorable, which has created an attractive climate for small and medium-sized companies with research intensive operations that are looking for capital to expand their operations," Mikael Brönnegård, Chief Executive Officer of NeuroVive, said.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NVP:SS kr51.00 SEK -0.25

NVP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for NVP.
View Industry Companies
 

Industry Analysis

NVP

Industry Average

Valuation NVP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 156.2x
Price/Book 12.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 157.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NEUROVIVE PHARMACEUTICAL, please visit www.neurovive.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.